Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ALLO – Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc.
ALLO
$1.44
Name : Allogene Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $314,753,920.00
EPSttm : -1.22
finviz dynamic chart for ALLO
Allogene Therapeutics, Inc.
$1.44
11.54%
$0.149

Float Short %

18.31

Margin Of Safety %

Put/Call OI Ratio

0.2

EPS Next Q Diff

0.03

EPS Last/This Y

0.31

EPS This/Next Y

0.04

Price

1.29

Target Price

8.15

Analyst Recom

1.36

Performance Q

-36.14

Relative Volume

0.49

Beta

0.31

Ticker: ALLO




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07ALLO1.1950.231.766802
2025-05-08ALLO1.1750.230.106857
2025-05-09ALLO1.150.230.016864
2025-05-12ALLO1.160.230.386924
2025-05-13ALLO1.130.230.076982
2025-05-14ALLO0.93110.200.237607
2025-05-15ALLO1.090.190.047819
2025-05-16ALLO1.110.190.017844
2025-05-19ALLO1.0950.270.504342
2025-05-20ALLO1.1650.270.024349
2025-05-21ALLO1.1150.240.004784
2025-05-22ALLO1.0950.220.005059
2025-05-23ALLO1.040.220.005059
2025-05-27ALLO1.0850.220.005062
2025-05-28ALLO1.120.220.045153
2025-05-29ALLO1.1850.220.035163
2025-05-30ALLO1.160.220.005193
2025-06-02ALLO1.2750.220.005224
2025-06-03ALLO1.3560.200.385588
2025-06-04ALLO1.280.200.005608
2025-06-05ALLO1.30.200.005640
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07ALLO1.2020.0- -1.20
2025-05-08ALLO1.1720.0- -1.20
2025-05-09ALLO1.1620.0- -1.20
2025-05-12ALLO1.1720.0- -1.20
2025-05-13ALLO1.1222.4- -1.20
2025-05-14ALLO0.9422.4- -1.20
2025-05-15ALLO1.0922.4- -1.20
2025-05-16ALLO1.1222.4- -1.04
2025-05-19ALLO1.0916.1- -1.01
2025-05-20ALLO1.1717.9- -1.01
2025-05-21ALLO1.1117.9- -1.01
2025-05-22ALLO1.0917.9- -1.01
2025-05-23ALLO1.0517.9- -1.01
2025-05-27ALLO1.0817.9- -1.01
2025-05-28ALLO1.1217.9- -1.01
2025-05-29ALLO1.1817.9- -1.01
2025-05-30ALLO1.1717.9- -1.01
2025-06-02ALLO1.2717.9- -1.01
2025-06-03ALLO1.3517.9- -1.01
2025-06-04ALLO1.2817.9- -1.01
2025-06-05ALLO1.2917.9- -1.01
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07ALLO-0.28-11.0722.91
2025-05-08ALLO-0.28-11.0722.91
2025-05-09ALLO-0.28-11.0722.91
2025-05-12ALLO-0.28-6.3921.04
2025-05-13ALLO-0.28-6.3921.04
2025-05-14ALLO-0.28-6.3921.04
2025-05-15ALLO-0.28-6.3921.04
2025-05-16ALLO-0.28-6.3920.96
2025-05-19ALLO-0.281.0720.15
2025-05-20ALLO-0.301.0720.15
2025-05-21ALLO-0.301.0720.15
2025-05-22ALLO-0.301.0720.15
2025-05-23ALLO-0.301.0720.15
2025-05-27ALLO-0.306.7620.15
2025-05-28ALLO-0.306.7618.31
2025-05-29ALLO-0.306.7618.31
2025-05-30ALLO-0.306.7618.31
2025-06-02ALLO-0.306.9818.31
2025-06-03ALLO-0.306.9818.31
2025-06-04ALLO-0.306.9818.31
2025-06-05ALLO-0.306.9818.31
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.28

Avg. EPS Est. Current Quarter

-0.26

Avg. EPS Est. Next Quarter

-0.25

Insider Transactions

-0.3

Institutional Transactions

6.98

Beta

0.31

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

10

Growth Score

25

Sentiment Score

40

Actual DrawDown %

97.3

Max Drawdown 5-Year %

-97.9

Target Price

8.15

P/E

Forward P/E

PEG

P/S

P/B

0.73

P/Free Cash Flow

EPS

-1.23

Average EPS Est. Cur. Y​

-1.01

EPS Next Y. (Est.)

-0.97

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.49

Return on Equity vs Sector %

-89.5

Return on Equity vs Industry %

-71.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.19

EBIT Estimation

Allogene Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 226
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today
news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance
stock history ALLO – Allogene Therapeutics, Inc. invest stock market
stock prices ALLO premarket after hours
ticker ALLO fair value insiders trading